AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23751748 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic protocol consisting of judgment possible site, determining probable etiology, checking and feedbacks on laboratory test in 12 hours, and reassessment and adjustment treatment in 48-72 hours.
Number of subjects: 65
Study 23751748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65
Study 20817937 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist geriatric input
Number of subjects: 225
Study 20817937 — intervention group
Group type: COMPARATOR
Intervention: Regular input
Number of subjects: 225
Study 18655241 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk muscle endurance training (6-week, 18-session program)
Number of subjects: 31
Study 18655241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 31
Study 17039734 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ketorolac
Number of subjects: 0
Study 17039734 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ketorolac
Number of subjects: 0
Study 17039734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 0
Study 12725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) during phototherapy
Number of subjects: 310
Study 12725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) on the unexposed forehead area after phototherapy
Number of subjects: 310
Study 12725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubinometry (TcB) on the exposed forehead and chest during phototherapy
Number of subjects: 310
Study 12725548 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-phototherapy TcB measurements
Number of subjects: 310
Study 12725548 — intervention group
Group type: COMPARATOR
Intervention: Control group measurements of TcB
Number of subjects: 310
Study 10690817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation (n = 616)
Number of subjects: 1229
Study 10690817 — intervention group
Group type: COMPARATOR
Intervention: No IOL implantation (n = 613)
Number of subjects: 1229
Study 9043839 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 162
Study 9043839 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (combined 20 mg and 40 mg)
Number of subjects: 162
Study 9043839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 7942516 — intervention group
Group type: EXPERIMENTAL
Intervention: Masks with lenses clouded to give seven levels of visual acuity
Number of subjects: 46
Study 3280388 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion for 5 or 10 hours daily in trial A (75 patients with grade 3 encephalopathy)
Number of subjects: 137
Study 3280388 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion for 10 hours daily in trial B (62 patients with grade 4 encephalopathy)
Number of subjects: 137
Study 3280388 — intervention group
Group type: COMPARATOR
Intervention: No-perfusion group in trial B (62 patients with grade 4 encephalopathy)
Number of subjects: 137
Study 3280388 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiologic subgroups (acetaminophen, hepatitis A, hepatitis B, presumed non-A, non-B hepatitis, halothane or drug reaction)
Number of subjects: 137
Study 31823793 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN utilization
Number of subjects: 629
Study 31823793 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in rural communities
Number of subjects: 629
Study 31823793 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women (aged < 30 years)
Number of subjects: 629
Study 30173448 — intervention group
Group type: EXPERIMENTAL
Intervention: Huanshao Capsules (HSC) at the dose of 3 capsules tid for 12 weeks
Number of subjects: 200
Study 30173448 — intervention group
Group type: COMPARATOR
Intervention: Wuziyanzong Pills at 6 g bid for 12 weeks
Number of subjects: 200
Study 26944022 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based, Individually‐tailored Physical activity Print (HIPP) intervention
Number of subjects: 84
Study 26944022 — intervention group
Group type: COMPARATOR
Intervention: Wellness contact control condition
Number of subjects: 84
Study 25089280 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with partially hydrolyzed guar gum (PHGG) for 10 months
Number of subjects: 165
Study 25089280 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (Control group)
Number of subjects: 165
Study 22681769 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL), 3-day, twice daily oral administration
Number of subjects: 549
Study 22681769 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 549
Study 19104169 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.075 microg x kg x h)
Number of subjects: 19
Study 19104169 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study 17879400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and oral antioxidants
Number of subjects: 100
Study 17879400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17879400 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of antioxidants
Number of subjects: 100
Study 15117604 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PlGF levels in pregnancies complicated by preeclampsia
Number of subjects: 177
Study 15117604 — intervention group
Group type: COMPARATOR
Intervention: Plasma PlGF levels in normal pregnancies
Number of subjects: 177
Study 15117604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in plasma PlGF levels
Number of subjects: 177
Study 15117604 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PlGF levels in pregnancies with other complications
Number of subjects: 177
Study 11876696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable CaCO3 tablets (750 mg, 1500 mg, 3000 mg)
Number of subjects: 20
Study 11876696 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent bicarbonate solution
Number of subjects: 20
Study 11876696 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowable CaCO3 tablets
Number of subjects: 20
Study 11876696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9568857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 41
Study 9568857 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate haemodialysis (BHD)
Number of subjects: 41
Study 7839963 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 at 60 sec delay
Number of subjects: 169
Study 7839963 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 at 45 sec delay
Number of subjects: 169
Study 7839963 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 240 at 60 sec delay
Number of subjects: 169
Study 7839963 — intervention group
Group type: COMPARATOR
Intervention: ioversol 240 at 45 sec delay
Number of subjects: 169
Study 7839963 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 320 at 60 sec delay
Number of subjects: 169
Study 7839963 — intervention group
Group type: COMPARATOR
Intervention: ioversol 320 at 45 sec delay
Number of subjects: 169
Study 2296985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A (200,000 IU)
Number of subjects: 1772
Study 2296985 — intervention group
Group type: COMPARATOR
Intervention: Control group (aged 3-5 years)
Number of subjects: 1772
Study 2296985 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 1-2 years
Number of subjects: 1772
Study 153679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofezone (1200 mg for the first week, 600 mg for the second week)
Number of subjects: 29
Study 153679 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (150 mg for the first week, 75 mg for the second week)
Number of subjects: 29
Study 153679 — intervention group
Group type: COMPARATOR
Intervention: Clofezone vs Diclofenac
Number of subjects: 29
Study 153679 — intervention group
Group type: COMPARATOR
Intervention: Clofezone and Diclofenac
Number of subjects: 29
Study 7223751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of allopurinol tablets (300 mg)
Number of subjects: 5
Study 7223751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter suppositories (300 mg allopurinol)
Number of subjects: 5
Study 7223751 — intervention group
Group type: COMPARATOR
Intervention: PEG suppositories (300 mg allopurinol)
Number of subjects: 5
Study 31709115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Edaravone Dexborneol (12.5 mg)
Number of subjects: 385
Study 31709115 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose Edaravone Dexborneol (37.5 mg)
Number of subjects: 385
Study 31709115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Edaravone Dexborneol (62.5 mg)
Number of subjects: 385
Study 31709115 — intervention group
Group type: COMPARATOR
Intervention: Edaravone (30 mg) - Control group
Number of subjects: 385
Study 28199364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐Molecular‐Weight Heparin (LMWH) - dalteparin (Fragmin®) 5000 IE once daily
Number of subjects: 63
Study 28199364 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 63
Study 25720712 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened antihypertensive (intravenous antihypertensive drugs controlled at 130‐140 mmHg for 24 h)
Number of subjects: 120
Study 25720712 — intervention group
Group type: COMPARATOR
Intervention: Normal antihypertensive (intravenous antihypertensive drugs controlled at 160‐180 mmHg for 24 h)
Number of subjects: 120
Study 25720712 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened antihypertensive
Number of subjects: 120
Study 25720712 — intervention group
Group type: COMPARATOR
Intervention: Normal antihypertensive
Number of subjects: 120
Study 24088416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented red ginseng (FRG) capsules
Number of subjects: 93
Study 24088416 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 93
Study 22324379 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-7158 (oral administration)
Number of subjects: 0
Study 19590350 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher redeemable for free safety devices and educational materials
Number of subjects: 542
Study 19590350 — intervention group
Group type: COMPARATOR
Intervention: Safety device ownership
Number of subjects: 542
Study 19590350 — intervention group
Group type: COMPARATOR
Intervention: Unsafe behaviors (stomach sleep position)
Number of subjects: 542
Study 17516307 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) at 30 to 45 seconds
Number of subjects: 65
Study 17516307 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 65
Study 17516307 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) at 5 to 10 seconds
Number of subjects: 65
Study 15359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management and community health worker interventions
Number of subjects: 0
Study 15359179 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12105831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily) + budesonide (9 mg once daily)
Number of subjects: 134
Study 12105831 — intervention group
Group type: COMPARATOR
Intervention: Placebo + budesonide (9 mg once daily)
Number of subjects: 134
Study 12105831 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (ciprofloxacin and metronidazole, both 500 mg twice daily)
Number of subjects: 134
Study 12105831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10527002 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Brien‐Fleming method
Number of subjects: 0
Study 10527002 — intervention group
Group type: COMPARATOR
Intervention: Pocock stopping boundaries
Number of subjects: 0
Study 10527002 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned interim analyses
Number of subjects: 0
Study 7782014 — intervention group
Group type: COMPARATOR
Intervention: Formalized follow-up protocols (e.g. bone scintigraphy, chest X-ray, abdominal ultrasound, mammography, laboratory investigations)
Number of subjects: 0
Study 7782014 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed strategy based on meticulous history-taking and clinical examination with psychosocial rehabilitation emphasis
Number of subjects: 0
Study 1704547 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 14
Study 1704547 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 14
Study 113807 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI) 150 mg/day for 6 weeks
Number of subjects: 49
Study 31451306 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 430
Study 31451306 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 430
Study 31451306 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 430
Study 31451306 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 430
Study 31451306 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 430
Study 31451306 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI or CABG
Number of subjects: 430
Study 28039551 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA) applied to the left dlPFC
Number of subjects: 20
Study 28039551 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not specified)
Number of subjects: 20
Study 25465295 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 575
Study 25465295 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 575
Study 23611977 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous UCB infusion, 1 year of daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes management
Number of subjects: 15
Study 23611977 — intervention group
Group type: COMPARATOR
Intervention: Intensive diabetes management alone
Number of subjects: 15
Study 21808028 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (45-min bout on an elliptical trainer)
Number of subjects: 12
Study 19047656 — intervention group
Group type: EXPERIMENTAL
Intervention: Artekin
Number of subjects: 0
Study 19047656 — intervention group
Group type: COMPARATOR
Intervention: Arterakine
Number of subjects: 0
Study 16952492 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-drug cocktail (flurbiprofen 50 mg, caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Number of subjects: 24
Study 16952492 — intervention group
Group type: COMPARATOR
Intervention: 5-drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquin 10 mg, chlorzoxazone 250 mg, dapsone 100 mg)
Number of subjects: 24
Study 16952492 — intervention group
Group type: COMPARATOR
Intervention: flurbiprofen alone (50 mg)
Number of subjects: 24
Study 15609591 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 0
Study 15609591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-General Anesthesia (AGA)
Number of subjects: 0
Study 15609591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Epidural-General Anesthesia (EGA)
Number of subjects: 0
Study 15609591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-Drug Anesthesia (AA)
Number of subjects: 0
Study 15609591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Acupuncture-Epidural-General Anesthesia (AEA)
Number of subjects: 0
Study 12366880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent targeted therapy
Number of subjects: 0
Study 12366880 — intervention group
Group type: COMPARATOR
Intervention: Continuous maintenance therapy
Number of subjects: 0
Study 9468465 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal thyrotropin-releasing hormone (400 microg each at eight-hour intervals, four doses)
Number of subjects: 996
Study 9468465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study 7876650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine by jet injector
Number of subjects: 0
Study 7876650 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine by needle
Number of subjects: 0
Study 7876650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine by needle
Number of subjects: 0
Study 7876650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hepatitis vaccines by needle in separate arms
Number of subjects: 0
Study 2137799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) with addition of AEOS-7EO
Number of subjects: 21
Study 2137799 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulfate (SLS) alone
Number of subjects: 21
Study 389352 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 2 g single dose
Number of subjects: 192
Study 389352 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 400 mg twice daily for five days
Number of subjects: 192
Study 30649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU single bolus followed by 4,000 IU daily for 16 weeks)
Number of subjects: 65
Study 30649593 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65
Study 30649593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 29512200 — intervention group
Group type: EXPERIMENTAL
Intervention: brodalumab 140 or 210 mg every 2 weeks (Q2W)
Number of subjects: 0
Study 29512200 — intervention group
Group type: EXPERIMENTAL
Intervention: brodalumab 210 mg Q2W
Number of subjects: 0
Study 29512200 — intervention group
Group type: COMPARATOR
Intervention: ustekinumab
Number of subjects: 0
Study 29512200 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 26969136 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 36°C
Number of subjects: 115
Study 26969136 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33°C
Number of subjects: 115
Study 25194420 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online decision aid (DA) for cholesterol self‐testing
Number of subjects: 1137
Study 25194420 — intervention group
Group type: COMPARATOR
Intervention: Limited information sheet for cholesterol self‐testing (Control)
Number of subjects: 1137
Study 25194420 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online decision aid (DA) for diabetes self‐testing
Number of subjects: 1137
Study 25194420 — intervention group
Group type: COMPARATOR
Intervention: Limited information sheet for diabetes self‐testing (Control)
Number of subjects: 1137
Study 25194420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues to action in the cholesterol condition
Number of subjects: 1137
Study 22558693 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic pressure simulation at 20 cm pulpal pressure
Number of subjects: 3
Study 22558693 — intervention group
Group type: COMPARATOR
Intervention: Hydrostatic pressure simulation but no pressure applied (positive control)
Number of subjects: 3
Study 22558693 — intervention group
Group type: COMPARATOR
Intervention: Conventional microleakage method
Number of subjects: 3
Study 20932521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement augmentation technique (group A, 40 patients)
Number of subjects: 80
Study 20932521 — intervention group
Group type: COMPARATOR
Intervention: Gamma Nail conventional technique (group B, 40 patients)
Number of subjects: 80
Study 20932521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement augmentation technique (group A)
Number of subjects: 80
Study 20932521 — intervention group
Group type: COMPARATOR
Intervention: Gamma Nail conventional technique (group B)
Number of subjects: 80
Study 17562493 — intervention group
Group type: EXPERIMENTAL
Intervention: GgHP (standardized herbal product from Galphimia glauca)
Number of subjects: 152
Study 17562493 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (1 mg)
Number of subjects: 152
Study 17562493 — intervention group
Group type: EXPERIMENTAL
Intervention: GgHP
Number of subjects: 152
Study 17562493 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 152
Study 16231337 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 30
Study 12375804 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 258
Study 12375804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 10481492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (added to one culture)
Number of subjects: 61
Study 10481492 — intervention group
Group type: COMPARATOR
Intervention: Control (no bleomycin added)
Number of subjects: 61
Study 10481492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal cancer patients with chromosome instability (b/c > 0.8)
Number of subjects: 61
Study 10481492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal cancer patients with chromosome oversensitivity to mutagens (b/c > 1)
Number of subjects: 61
Study 10481492 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased chromosome instability
Number of subjects: 61
Study 7573998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 24
Study 7573998 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 24
Study 7573998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and epidural clonidine
Number of subjects: 24
Study 2015917 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving treatment
Number of subjects: 163
Study 2015917 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy
Number of subjects: 163
Study 2015917 — intervention group
Group type: COMPARATOR
Intervention: Choice of treatment
Number of subjects: 163
Study 7166146 — intervention group
Group type: EXPERIMENTAL
Intervention: Success group
Number of subjects: 0